Sequoia Pharmaceuticals Inc is categorized under Commercial Medical Research in Gaithersburg, MD and active since 2001.
Sequoia Pharmaceuticals Inc was established in 2001, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Steven D Skolsky at the company’s single location by writing to 267 Kentlands Boulevard 905, Gaithersburg, Maryland MD 20878 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Sequoia Pharmaceuticals Inc |
| Contact Person: | Steven D Skolsky |
| Address: | 267 Kentlands Boulevard 905, Gaithersburg, Maryland 20878 |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 2001 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Sequoia Pharmaceuticals Inc was started in 2001 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Steven D Skolsky for inquiries that concern Sequoia Pharmaceuticals Inc by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Sequoia Pharmaceuticals Inc can be found at the coordinates 39.123371,-77.23614 as well as the street address 267 Kentlands Boulevard 905 in Gaithersburg, Maryland 20878.
For its online presence, you may visit Sequoia Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.